Eval CONPARMED Haute-Bretagne : Guaranteeing the Continuity of the Care Pathway for the Elderly Patient: Evaluation of a Territorial Approach of Clinical Pharmacy
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Medication Reconciliation at Discharge
- Sponsor
- Rennes University Hospital
- Enrollment
- 443
- Locations
- 3
- Primary Endpoint
- Adverse drug event-related hospital revisits
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
In the context of the ageing of the French population, drug iatrogeny in the elderly is a major public health issue, responsible for approximately 7,500 deaths per year and 3.4% of hospitalizations among patients aged 65 and over.
The interest of the Medication Reconciliation (MR) in reducing medication errors and unintentional discrepancies in prescriptions at transition points in patients' medication care pathways no longer seems to be in doubt both in France and abroad.
On the other hand, the literature on the clinical impact of these drug errors (i. e. occurrence of an adverse drug event (ADE) or readmission rates) is currently limited in France and presents variable results abroad.
Detailed Description
The medication reconciliation implementation mobilizes human resources (pharmacists, pharmacy technician, nurses...) and constitutes an investment for healthcare institutions. However, the resulting improvement in patients' health status (and the potential reduction in ADEs) could reduce their care consumption and thus reduce costs from a healthcare system perspective. We therefore propose to assess the cost-effectiveness of this care strategy. Finally, we will study the impact of the MR deployment on existing professional organizations, both in hospital and between community healthcare professionals and hospital as well as its conditions of implementation.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Adverse drug event-related hospital revisits
Time Frame: 30 days after discharge
Rate of adverse drug event-related hospital revisits within 30 days after discharge
Secondary Outcomes
- General Practitioner consultation(30 days after discharge)
- All-causes readmissions and/or Emergency Department visits(90 days after discharge)
- Incremental Cost-Effectiveness Ratio (ICER) at Day 30(30 days after discharge)
- Incremental Cost-Effectiveness Ratio (ICER) at Day 90(90 days after discharge)
- Patient reported experience measures(7 days after discharge)
- Number of Unintended Medication Discrepancies(At admission)
- Impact of the implementation of the intervention on professional organizations(Before and after the implementation of the intervention in the participating wards)
- Severity of Unintended Medication Discrepancies(At admission)